Program
elecoglipron
Also written as “Elecoglipron”, “AZD5004” and “ECC5004”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Heart Failure · Renal Insufficiency, Chronic · Renal Insufficiency, led by 2 companies.
Drug pageElecoglipron: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 2211 open or running | phase 3since Jun 18, 2026 | Aug 13, 2024 | Nov 18, 2026phase 1 · NCT07723833 |
| Eccogene | 40 open or running | phase 1since Dec 8, 2022 | Dec 8, 2022 | none ahead |
- Named in AstraZeneca’s own pipeline as
elecoglipron
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel and Quotient Sciences.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseAstraZeneca licensed it from Eccogene, for everywhere outside China, where the two develop and sell it together.Announced Nov 9, 2023 · Source: AstraZeneca, Nov 9, 2023
History and studies of Eccogene only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 8, 2022First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05654831 · 69 enrolled · United States
- Nov 9, 2023AstraZeneca licensed it from EccogeneLicenseEverywhere outside China, where the two develop and sell it together · announced · AstraZeneca
- Feb 13, 20242 phase 1 studies in Diabetes Mellitus, Type 2NCT06268145, NCT06293742
- Feb 13, 2025Named elecoglipronINNProposed as its International Nonproprietary Name in WHO's List 132 · before, AZD5004, ECC5004
- May 16, 2025Phase 1 study in ObesityNCT06988553 · 45 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 Eccogene leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06988553Obesity · China | 1 | Completed | Nov 28, 2025 | 45 |
| NCT06293742Diabetes Mellitus, Type 2 · United States | 1 | Completed | Apr 15, 2024 | 48 |
| NCT06268145Diabetes Mellitus, Type 2 · United States | 1 | Completed | Mar 29, 2024 | 14 |
| NCT05654831Diabetes Mellitus, Type 2 · United States | 1 | Completed | Nov 1, 2023 | 69 |
How it is read
Names in the registry
- “Elecoglipron”, 10 entries
- “AZD5004”, 10 entries
- “ECC5004”, 3 entries
- “Elecoglipron Reference Formulation Dose A”, 1 entry
- “Elecoglipron Reference Formulation Dose B”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Obesity, 5 studies
- Heart Failure, 1 study
- Renal Insufficiency, Chronic, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.